Encouraging immune responses and a competitive safety profile in a small trial seem to make Novavax’s vaccine a contender.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.